FierceBiotech Jan 8, 2026 Lilly links up with InduPro in next-gen cancer treatment deal worth up to $950M
Endpoints News Dec 22, 2025 Aktis Oncology files for IPO to fund Lilly-partnered radiopharma pipeline
BioPharma Dive Dec 18, 2025 Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Endpoints News Dec 18, 2025 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
FierceBiotech Dec 11, 2025 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
Endpoints News Dec 11, 2025 Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported